Voyager Therapeutics competitors

Ron Cohen, M.D., President and Chief Executive Officer, founded Acorda Therapeutics, Inc. in 1995. Previously he was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen is a member of the Executive Committee and Vice Chair of the Health Section of the Biotechnology Industry Organization (BIO), and serves on the Board of Directors of Dyax Corp. He previously served as Director and Chairman of the New York Biotechnology Association (NYBA). He also serves as a member the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University’s Alumni Medal for Distinguished Service. Dr. Cohen was named NeuroInvestment’s (now called NeuroPerspective) CEO of the Year and was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. He is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region and is an inductee of the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.” In 2010, Dr. Cohen was recognized by the New York Biotechnology Association as the NYBA “The Cure Starts Here” Business Leader of the Year.

Chaim Lebovits has been at the forefront of mining and natural resource management in African regions for over a decade. He has spent years leading the exploration and development of resources in the Democratic Republic of Congo on behalf of world-leading firms. In this capacity, he has negotiated numerous, highly-successful deals on behalf of both African governments and global mining concerns. As an internationally known and respected business mogul and corporate manager, Lebovits has developed excellent personal relations with numerous African leaders, and has promoted the interests of their countries in the economic and political capitals of the world, both in official and unofficial capacities. Lebovits leads ACC HOLDINGS INTERNATIONAL and its many subsidiaries with his extensive experience and passion for the mining, oil, and energy industry, with intentions of taking ACC to a level of excellence and leadership in the resource mining sector. His commitment to the people that work with him, and to health, environmental and social issues, is evident in his projects in Africa. Lebovits into BrainStorm through ACCBT (ACC BioTech). ACCBT is one of ACC's subsidiaries that is totally focused on biotechnology. Originally from New York, Lebovits moved to Israel and now resides in Jerusalem. Lebovits has worked in senior positions for the worldwide Chabad Lubavitch organization and in the mining business, and launched his own private companies in 2005. Lebovits now splits his time between North America, Europe, Africa, and the Middle East.

Geoff is a pioneer in cell and gene therapy with a track record of successful leadership at innovative biotechs. He is the former CEO of Organogenesis Inc., the world’s leading cell therapy company. During his tenure at the helm, the company treated 1 million patients with living cell therapies, received the first approval of an allogeneic cell therapy from the FDA’s Center for Biologics Evaluation and Research and led the field of regenerative medicine. Geoff is also the founding CEO of eGenesis, a biotech dedicated to applying CRISPR Cas-9 gene editing to xenotransplantation. Earlier in his career, Geoff spent 11 years at Novartis in senior leadership positions within the global transplantation and immunology franchise. Geoff sits on the boards of Talaris Therapeutics and Satellos Bioscience. Past activities include chairman of the board of MassBio, chairman of the board of the Alliance of Regenerative Medicine, and a member of the advisory council to the Health Policy Commission for Massachusetts.

Rick has helped bring transformative medicines to patients in more than 10 diseases across multiple successful biotech companies. Before joining Affinia Therapeutics, Rick was Chief Business Officer at AveXis where he played a significant role in the company's build and sale to Novartis for $8.7 billion and the launch of Zolgensma®, its flagship gene therapy product. Prior to AveXis, Rick was Chief Business Officer at Catabasis Pharmaceuticals and before that, a Senior Vice President in the commercial group at InterMune until its acquisition by Roche. Before this, Rick held roles of increasing responsibility at MedImmune (AstraZeneca) and at Centocor (J&J). Before joining the industry, Rick practiced as a clinical pharmacist in a hospital setting. He received his B.S. in Pharmacy from the University of Iowa and his M.B.A. from the Wharton School.